---
title: "Ocrevus (ocrelizumab) in multiple sclerosis: Safety questions"
description: "Safety questions on Ocrevus (ocrelizumab) in multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Monitoring, Side effects, and Warnings. Questions: What tests are needed before starting Ocrevus or Ocrevus Zunovo? How long are patients monitored after an Ocrevus or Ocrevus Zunovo dose? How common are infusion reactions with Ocrevus IV? How common are injection reactions with Ocrevus Zunovo? 13 further questions follow. 17 questions quoted from 7 sources."
canonical: "https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ocrevus (ocrelizumab) in multiple sclerosis: Safety questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Ocrevus](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf), [Ocrevus Zunovo](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf)

Questions that apply to every indication of Ocrevus are on [Ocrevus (ocrelizumab), all indications](https://www.evicenter.com/medical-information/ocrevus).

## Monitoring

<a id="ocrevus-tests-before-starting"></a>

### What tests are needed before starting Ocrevus or Ocrevus Zunovo?

> “PRIOR TO THE FIRST INFUSION
>
> Perform hepatitis B virus screening<sup>2</sup>
> Test for quantitative serum immunoglobulins<sup>2</sup>
> Complete necessary vaccinations (4 weeks prior to live or live-attenuated vaccines and, when possible, at least 2 weeks prior for non-live vaccines)<sup>2</sup>
> Obtain serum aminotransferases (ALT and AST), alkaline phosphatase, and bilirubin levels<sup>2</sup>
>
> PRIOR TO EVERY INFUSION
>
> Determine whether there is an active infection. In case of active infection, delay infusion of OCREVUS until the infection resolves<sup>2</sup>”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=PRIOR%20TO%20THE%20FIRST%20INFUSION,of%20OCREVUS%20until%20the%20infection)

This passage is in a collapsed section of the page; select: PRIOR TO THE FIRST INFUSION, then PRIOR TO EVERY INFUSION

> “PRIOR TO THE FIRST DOSE
>
> Perform hepatitis B virus screening<sup>1</sup>
> Test for quantitative serum immunoglobulins<sup>1</sup>
> Complete necessary vaccinations (≥4 weeks prior to live or live-attenuated vaccines and, when possible, at least 2 weeks prior for non-live vaccines)<sup>1</sup>
> Obtain serum aminotransferases (ALT and AST), alkaline phosphatase, and bilirubin levels<sup>1</sup>”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=PRIOR%20TO%20THE%20FIRST%20DOSE,AST%29%2C%20alkaline%20phosphatase%2C%20and%20bilirubin)

This passage is in a collapsed section of the page; select: PRIOR TO THE FIRST DOSE

<a id="ocrevus-post-dose-observation"></a>

### How long are patients monitored after an Ocrevus or Ocrevus Zunovo dose?

> “Observe patients for at least 1 hour after the completion of the infusion
> Inform patients that infusion reactions can occur up to 24 hours after infusion”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Observe%20patients%20for%20at%20least,to%2024%20hours%20after%20infusion)

> “Monitor patients closely during all injections for at least 1 hour after the initial injection and for at least 15 minutes after subsequent injections<sup>1*</sup>”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=Monitor%20patients%20closely%20during%20all,least%2015%20minutes%20after%20subsequent)

This passage is in a collapsed section of the page; select: POST-DOSE OBSERVATION

## Side effects

<a id="ocrevus-infusion-reactions"></a>

### How common are infusion reactions with Ocrevus IV?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “In OCREVUS MS clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. In adults, the incidence of infusion reactions in patients treated with OCREVUS was 34% to 40%. There were no fatal infusion reactions, but 0.3% of patients with MS who were treated with OCREVUS experienced infusion reactions that were serious, some requiring hospitalization.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=In%20OCREVUS%20MS%20clinical%20trials%2C,were%20serious%2C%20some%20requiring%20hospitalization.)

> “Symptoms of infusion reactions can include pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, tachycardia, and anaphylaxis. These reactions are more commonly reported with the first infusion.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Symptoms%20of%20infusion%20reactions%20can,reported%20with%20the%20first%20infusion.)

> “Studies 1 and 2 
> OCREVUS 
> 600 mg IV 
> Every 24 Weeks<sup>1</sup> 
> (n=825) 
> % 
> REBIF 
> 44 mcg SQ 
> 3 Times per Week 
> (n=826) 
> %”

Source: [OCREVUS: OCREVUS \[IV\], page 12, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=12)

> “Infusion reactions 
> 34 
> 10”

Source: [OCREVUS: OCREVUS \[IV\], page 12, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=12)

> “Study 3 
> OCREVUS 
> 600 mg IV 
> Every 24 
> Weeks<sup>1</sup> 
> (n=486) 
> % 
> Placebo 
>
>
>
> (n=239) 
> %”

Source: [OCREVUS: OCREVUS \[IV\], page 13, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=13)

> “Infusion reactions 
> 40 
> 26”

Source: [OCREVUS: OCREVUS \[IV\], page 13, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=13)

> “Infusion reactions were highest with the first infusion”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=Infusion%20reactions%20were%20highest%20with%20the%20first%20infusion)

Note: The rates are from Tables 4 (RMS, OPERA I and II) and 5 (PPMS, ORATORIO) of the OCREVUS Prescribing Information. REBIF-treated patients received placebo infusions every 24 weeks, and the PPMS comparator was placebo infusions.

<a id="ocrevus-injection-reactions"></a>

### How common are injection reactions with Ocrevus Zunovo?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “In Study 4, injection reactions occurred in 49% (58/118) of patients after the first injection of OCREVUS 
> ZUNOVO. Of these 118 patients, 47% and 11% experienced at least one local injection reaction and one systemic 
> injection reaction, respectively. The most common symptoms reported by patients with local and systemic 
> injection reactions included: injection site erythema, injection site pain, injection site swelling, injection site 
> pruritus, headache, and nausea. Among the patients experiencing an injection reaction, the majority of patients 
> (83%) had injection reactions occur within 24 hours after the end of the injection, as opposed to during the 
> injection (19%). All injection reactions were of mild (73%) or moderate (27%) severity. The median duration of 
> symptoms was 3 days for systemic injection reactions and 3.5 days for local injection reactions. All patients 
> recovered from injection reactions, of which 26% required symptomatic treatment. 
> For subsequent injections, among the 118 patients who received OCREVUS ZUNOVO only throughout the study, 
> the frequency of local injection reactions ranged from 31% to 43% and the frequency of systemic injection 
> reactions ranged from 3% to 7% from Injection 2 to Injection 4. All injection reactions were of mild or moderate 
> severity.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 11, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=11)

> “There were no injection reactions that led to treatment discontinuation”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/safety.html#:~:text=There%20were%20no%20injection%20reactions%20that%20led%20to%20treatment%20discontinuation)

Note: Study 4 of the OCREVUS ZUNOVO Prescribing Information is OCARINA II, an open-label trial.

<a id="ocrevus-reaction-management"></a>

### How are Ocrevus infusion reactions and Ocrevus Zunovo injection reactions managed?

> “Modify the infusion rate in response to the severity of the reaction. For infusion reactions that are not life-threatening, the change in infusion rate will increase the duration of the infusion but not the total dose<sup>2</sup>
> MILD/MODERATE
> Reduce the infusion rate to half the rate of when the reaction began and maintain the reduced rate for at least 30 minutes. If tolerated, increase the infusion rate according to the initial infusion schedule.
> SEVERE
> Interrupt the infusion immediately and provide supportive treatment. Only restart the infusion after all symptoms have been resolved, at half the infusion rate of when the reaction began.
> LIFE-THREATENING OR DISABLING
> Immediately stop the infusion and provide appropriate supportive treatment. Permanently discontinue OCREVUS in these patients.”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Modify%20the%20infusion%20rate%20in,discontinue%20OCREVUS%20in%20these%20patients.)

> “Management recommendations depend on the type and severity of the reaction. For life-threatening reactions, immediately and permanently stop OCREVUS ZUNOVO or OCREVUS and administer appropriate supportive treatment. For less severe OCREVUS ZUNOVO injection reactions, the injection should be interrupted immediately, and the patient should receive symptomatic treatment. The injection should be completed at the healthcare provider’s discretion and only after all symptoms have resolved. For less severe OCREVUS infusion reactions, management may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Management%20recommendations%20depend%20on%20the,rate%2C%20and%2For%20administering%20symptomatic%20treatment.)

<a id="ocrevus-common-side-effects"></a>

### What are the most common side effects of Ocrevus?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “Studies 1 and 2 
> OCREVUS 
> 600 mg IV 
> Every 24 Weeks<sup>1</sup> 
> (n=825) 
> % 
> REBIF 
> 44 mcg SQ 
> 3 Times per Week 
> (n=826) 
> % 
> Upper respiratory tract infections 
> 40 
> 33 
> Infusion reactions 
> 34 
> 10 
> Depression 
> 8 
> 7 
> Lower respiratory tract infections 
> 8 
> 5 
> Back pain 
> 6 
> 5 
> Herpes virus- associated infections 
> 6 
> 4 
> Pain in extremity 
> 5 
> 4”

Source: [OCREVUS: OCREVUS \[IV\], page 12, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=12)

> “Study 3 
> OCREVUS 
> 600 mg IV 
> Every 24 
> Weeks<sup>1</sup> 
> (n=486) 
> % 
> Placebo 
>
>
>
> (n=239) 
> % 
> Upper respiratory tract infections 
> 49 
> 43 
> Infusion reactions 
> 40 
> 26 
> Skin infections 
> 14 
> 11 
> Lower respiratory tract infections 
> 10 
> 9 
> Cough 
> 7 
> 3 
> Diarrhea 
> 6 
> 5 
> Edema peripheral 
> 6 
> 5 
> Herpes virus associated infections 
> 5 
> 4”

Source: [OCREVUS: OCREVUS \[IV\], page 13, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=13)

> “The most common adverse reaction observed with OCREVUS ZUNOVO in adult patients with RMS and PPMS was injection reactions (incidence of 49%).”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=The%20most%20common%20adverse%20reaction%20observed,injection%20reactions%20%28incidence%20of%2049%25%29.)

Note: The rates are from Tables 4 (RMS, OPERA I and II, OCREVUS vs REBIF) and 5 (PPMS, ORATORIO, OCREVUS vs placebo) of the OCREVUS Prescribing Information, which list adverse reactions with an incidence of at least 5% for OCREVUS and higher than the comparator.

<a id="ocrevus-anti-drug-antibodies"></a>

### Do people develop antibodies against Ocrevus?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “In Studies 1, 2, and 3, 12 (~1%) out of 1131 adult patients tested positive for ADAs, of which 2 patients tested 
> positive for neutralizing antibodies.”

Source: [OCREVUS: OCREVUS \[IV\], page 18, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=18)

> “These data are not adequate to assess the impact of ADAs on the safety and efficacy of OCREVUS.”

Source: [OCREVUS: OCREVUS \[IV\], page 18, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=18)

Note: Studies 1, 2, and 3 of the OCREVUS Prescribing Information are OPERA I, OPERA II, and ORATORIO.

## Warnings

<a id="ocrevus-infections"></a>

### Does Ocrevus increase the risk of infections?

> “Serious, including life-threatening or fatal, bacterial, viral, parasitic and fungal infections have been reported in patients receiving ocrelizumab. An increased risk of infections (including serious and fatal bacterial, fungal, and new or reactivated viral infections) has been observed in patients during and following completion of treatment with anti-CD20 B-cell depleting therapies.
>
> A higher proportion of adult patients treated with OCREVUS experienced infections compared to patients taking REBIF or placebo. In RMS trials in adults, 58% of patients treated with OCREVUS experienced one or more infections compared to 52% of patients treated with REBIF. In the PPMS trial, 70% of patients treated with OCREVUS experienced one or more infections compared to 68% of patients on placebo. Ocrelizumab increases the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Serious%2C%20including%20life%2Dthreatening%20or%20fatal%2C,skin%20infections%2C%20and%20herpes%2Drelated%20infections.)

> “Delay administration of ocrelizumab in patients with an active infection until the infection has resolved.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Delay%20administration%20of%20ocrelizumab%20in,until%20the%20infection%20has%20resolved.)

> “A higher proportion of adult patients treated with OCREVUS experienced respiratory tract infections compared to patients taking REBIF or placebo. In RMS trials in adults, 40% of patients treated with OCREVUS experienced upper respiratory tract infections compared to 33% of patients treated with REBIF, and 8% of patients treated with OCREVUS experienced lower respiratory tract infections compared to 5% of patients treated with REBIF. In the PPMS trial, 49% of patients treated with OCREVUS experienced upper respiratory tract infections compared to 43% of patients on placebo and 10% of patients treated with OCREVUS experienced lower respiratory tract infections compared to 9% of patients on placebo. The infections were predominantly mild to moderate and consisted mostly of upper respiratory tract infections and bronchitis.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Respiratory%20Tract%20Infections-,A%20higher%20proportion%20of%20adult%20patients%20treated%20with%20OCREVUS%20experienced,respiratory%20tract%20infections%20and%20bronchitis.)

> “Serious infections in the OCREVUS all-exposure population: 2.2 per 100 PY (95% CI: 2.0, 2.4) as of November 2023<sup>5,9</sup>”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=Serious%20infections%20in%20the%20OCREVUS,2.0%2C%202.4%29%20as%20of%20November)

> “The most common serious infections were urinary tract infections, pneumonia, and cellulitis<sup>5,9</sup>”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=The%20most%20common%20serious%20infections%20were%20urinary%20tract%20infections%2C%20pneumonia%2C%20and)

Note: The all-exposure population includes patients from the controlled trials, their open-label extensions, and other ocrelizumab studies.

<a id="ocrevus-herpes"></a>

### Does Ocrevus increase the risk of herpes or shingles?

> “In active-controlled (RMS) clinical trials in adults, herpes infections were reported more frequently in patients treated with OCREVUS than in patients treated with REBIF, including herpes zoster (2.1% vs. 1.0%), herpes simplex (0.7% vs. 0.1%), oral herpes (3.0% vs. 2.2%), genital herpes (0.1% vs. 0%), and herpes virus infection (0.1% vs. 0%). Infections were predominantly mild to moderate in severity. In the placebo-controlled (PPMS) clinical trial, oral herpes was reported more frequently in the patients treated with OCREVUS than in the patients on placebo (2.7% vs. 0.8%).
>
> Serious cases of infections caused by herpes simplex virus and varicella zoster virus, including central nervous system infections (encephalitis and meningitis), intraocular infections, and disseminated skin and soft tissue infections, have been reported in the postmarketing setting in multiple sclerosis patients receiving ocrelizumab. Serious herpes virus infections may occur at any time during treatment with ocrelizumab. Some cases were life-threatening.
>
> If serious herpes infections occur, treatment with ocrelizumab should be discontinued or withheld until the infection has resolved, and appropriate treatment should be administered.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=In%20active%2Dcontrolled%20%28RMS%29%20clinical%20trials,appropriate%20treatment%20should%20be%20administered.)

<a id="ocrevus-hepatitis-b"></a>

### Is hepatitis B screening required before Ocrevus or Ocrevus Zunovo?

> “Hepatitis B virus (HBV) reactivation has been reported in MS patients treated with ocrelizumab in the postmarketing setting. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with ocrelizumab. Do not administer ocrelizumab to patients with active HBV confirmed by positive results for HBsAg and anti-HB tests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Hepatitis%20B%20virus%20%28HBV%29%20reactivation,before%20starting%20and%20during%20treatment.)

> “Treatment with ocrelizumab is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening administration reactions to ocrelizumab.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Treatment%20with%20ocrelizumab%20is%20contraindicated,life%2Dthreatening%20administration%20reactions%20to%20ocrelizumab.)

<a id="ocrevus-pml"></a>

### Can Ocrevus cause progressive multifocal leukoencephalopathy (PML)?

> “Cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients with MS treated with ocrelizumab in the postmarketing setting. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in patients who are immunocompromised, and that usually leads to death or severe disability. PML has occurred in ocrelizumab-treated patients who had not been treated previously with natalizumab, (which has a known association with PML), were not taking any immunosuppressive or immunomodulatory medications associated with risk of PML prior to or concomitantly with ocrelizumab and did not have any known ongoing systemic medical conditions resulting in compromised immune system function.
>
> JCV infection resulting in PML has also been observed in patients treated with other anti-CD20 antibodies and other MS therapies.
>
> At the first sign or symptom suggestive of PML, withhold treatment with ocrelizumab-containing products and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.
>
> Magnetic resonance imaging (MRI) findings may be apparent before clinical signs or symptoms of PML. Monitoring with MRI for signs consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present. If PML is confirmed, treatment with ocrelizumab should be discontinued.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Cases%20of%20progressive%20multifocal%20leukoencephalopathy,with%20ocrelizumab%20should%20be%20discontinued.)

<a id="ocrevus-low-immunoglobulins"></a>

### Does Ocrevus lower immunoglobulin (IgG) levels?

> “As expected with any B-cell depleting therapy, decreased immunoglobulin levels are observed with ocrelizumab treatment. The pooled data of OCREVUS clinical studies (RMS and PPMS) in adults and their open-label extensions (up to approximately 7 years of exposure) have shown an association between decreased levels of immunoglobulin G (IgG<LLN) and increased rates of serious infections. Monitor the levels of quantitative serum immunoglobulins during treatment with ocrelizumab and after discontinuation of treatment, until B-cell repletion, and especially in the setting of recurrent serious infections. Consider discontinuing treatment with ocrelizumab in patients with serious opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=As%20expected%20with%20any%20B%2Dcell,requires%20treatment%20with%20intravenous%20immunoglobulins.)

> “In the active-controlled (RMS) trials (Study 1 and Study 2), the proportion of patients at baseline reporting IgG, 
> IgA, and IgM below the lower limit of normal (LLN) in OCREVUS-treated patients was 0.5%, 1.5%, and 0.1%, 
> respectively. Following treatment, the proportion of OCREVUS-treated patients reporting IgG, IgA, and IgM 
> below the LLN at 96 weeks was 1.5%, 2.4%, and 16.5%, respectively. 
> In the placebo-controlled (PPMS) trial (Study 3), the proportion of patients at baseline reporting IgG, IgA, and 
> IgM below the LLN in OCREVUS-treated patients was 0.0%, 0.2%, and 0.2%, respectively. Following 
> treatment, the proportion of OCREVUS-treated patients reporting IgG, IgA, and IgM below the LLN at 120 
> weeks was 1.1%, 0.5%, and 15.5%, respectively.”

Source: [OCREVUS: OCREVUS \[IV\], page 13, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=13)

> “Out of 2092 patients treated with OCREVUS, 62 serious infections were observed in 46 patients during episodes of IgG<LLN (OPERA, ORATORIO, and OLE)<sup>10,11</sup>”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=Out%20of%202092%20patients%20treated,of%20IgG%3CLLN%20%28OPERA%2C%20ORATORIO%2C%20and)

<a id="ocrevus-malignancy-breast-cancer"></a>

### Does Ocrevus increase the risk of cancer, including breast cancer?

> “An increased risk of malignancy with ocrelizumab may exist. In controlled trials, malignancies, including breast cancer, occurred more frequently in patients treated with OCREVUS. Breast cancer in adults occurred in 6 of 781 females treated with OCREVUS and none of 668 females treated with REBIF or placebo. Patients should follow standard breast cancer screening guidelines.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=An%20increased%20risk%20of%20malignancy,standard%20breast%20cancer%20screening%20guidelines.)

> “Breast cancer was found in:
>
> 6/781 females treated with OCREVUS and 0/668 females treated with Rebif or placebo in the controlled period<sup>2</sup>
> 35/3857 females on OCREVUS (18,207 PY) in the all-exposure population as of November 2023<sup>12</sup>”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=Breast%20cancer%20was%20found%20in%3A,all%2Dexposure%20population%20as%20of%20November)

Note: The all-exposure population includes patients from the controlled trials, their open-label extensions, and other ocrelizumab studies.

<a id="ocrevus-vaccines"></a>

### Can people taking Ocrevus get vaccines, including live vaccines?

> “Administer all age-appropriate immunizations according to immunization guidelines at least 4 weeks prior to initiation of ocrelizumab treatment for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ocrelizumab treatment for non-live vaccines. Ocrelizumab may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines following treatment with ocrelizumab has not been studied, and vaccination with live-attenuated or live vaccines is not recommended during treatment and until B-cell repletion.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Administer%20all%20age%2Dappropriate%20immunizations%20according,treatment%20and%20until%20B%2Dcell%20repletion.)

> “In infants of mothers exposed to ocrelizumab during pregnancy, do not administer live or live-attenuated vaccines before confirming the recovery of B-cell counts as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. If indicated, non-live vaccines may be administered prior to recovery from B-cell depletion, but assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to assess whether a protective immune response was mounted.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=In%20infants%20of%20mothers%20exposed,protective%20immune%20response%20was%20mounted.)

<a id="ocrevus-colitis"></a>

### Can Ocrevus cause colitis?

> “Immune-mediated colitis, which can present as a severe and acute-onset form of colitis, has been reported in patients receiving ocrelizumab in the postmarketing setting. Some cases of colitis were serious, requiring hospitalization, with a few patients requiring surgical intervention. Systemic corticosteroids were required in many of these patients. The time from treatment initiation to onset of symptoms in these cases ranged from a few weeks to years. Monitor patients for immune-mediated colitis during ocrelizumab treatment and evaluate promptly if signs and symptoms that may indicate immune-mediated colitis, such as new or persistent diarrhea or other gastrointestinal signs and symptoms, occur.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Immune%2Dmediated%20colitis%2C%20which%20can%20present,gastrointestinal%20signs%20and%20symptoms%2C%20occur.)

<a id="ocrevus-liver-injury"></a>

### Can Ocrevus cause liver damage?

> “Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including ocrelizumab. Signs of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred from weeks to months after administration.
>
> Patients treated with ocrelizumab found to have an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN are potentially at risk for severe drug-induced liver injury.
>
> Obtain liver function tests prior to initiating treatment with ocrelizumab, and monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury is present and an alternative etiology is not identified, discontinue ocrelizumab.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Clinically%20significant%20liver%20injury%2C%20without,is%20not%20identified%2C%20discontinue%20ocrelizumab.)

<a id="ocrevus-contraindications"></a>

### Who should not take Ocrevus (contraindications)?

> “Treatment with ocrelizumab is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening administration reactions to ocrelizumab. OCREVUS ZUNOVO is also contraindicated in patients with a history of hypersensitivity to ocrelizumab, hyaluronidase, or any component of OCREVUS ZUNOVO.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Treatment%20with%20ocrelizumab%20is%20contraindicated,any%20component%20of%20OCREVUS%20ZUNOVO.)

## Related pages
- [Medical information: Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/real-world-evidence)
- [Specific populations](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/storage-and-supply)
